Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A large US claims-based cohort suggests that most open-angle glaucoma suspects have modest annual conversion risk after the first year, and that age- and treatment-informed surveillance intervals may help tailor follow-up intensity.
In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.
A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.
A large U.S. study found that a contrast sensitivity score of 1.60 logCS marks the point where older adults are more likely to experience everyday vision disability, even when standard visual acuity may seem acceptable.
A multinational OHDSI network analysis found no meaningful association between semaglutide use and neovascular age-related macular degeneration among adults with type 2 diabetes across cohort and self-controlled designs.
In preperimetric glaucoma, baseline microvasculature dropout on OCTA predicted faster capillary density loss and a higher risk of later visual field damage, suggesting it may help identify eyes needing closer follow-up.
Eyes with preperimetric glaucoma and baseline microvasculature dropout progressed faster in capillary density loss and were more likely to develop visual field damage.
Three-dimensional eye shape on MRI predicted 15-year outcomes in high myopia. Nasally distorted and conical eyes had the highest risk of rapid elongation, macular thinning, myopic degeneration, and visual field defects.
A 2026 Ophthalmology report identified a pain-predominant dry eye phenotype in 6.9% of patients, marked by high symptom burden, minimal surface signs, and enrichment for migraine and psychiatric comorbidity.
OCT imaging revealed that inactive MFCPU/PIC lesions commonly show Bruch’s membrane disruption, inner retinal herniation, and focal choroidal excavation, helping distinguish them from inflammatory and infectious mimickers.
Ocular inflammation was linked to a higher risk of anti-adalimumab antibody formation in patients treated with adalimumab. More than 20% developed antibodies, supporting closer monitoring and therapeutic drug testing in high-risk patients.
This study found that younger age, better baseline vision, smaller hemorrhage size, and thicker subfoveal choroid predicted better 1-year visual outcomes after fovea-involving submacular hemorrhage from nAMD or PCV.
In patients with unilateral exudative AMD, double-layer sign on OCT was common, but OCT angiography showed nonexudative macular neovascularization in only about 40% of DLS-positive fellow eyes.
A 2026 Ophthalmology study suggests that combining CTG18.1 expansion testing with a FECD-specific polygenic risk score can improve prediction of keratoplasty risk across independent cohorts.
A rare, severe neurologic complication has been linked to general anesthesia in patients of maternal Venezuelan descent. Ophthalmologists should screen for ancestry and family history, involve anesthesiology early, and consider genetic eval
Optical genome mapping and long-read sequencing uncovered a tiny balanced rearrangement that separated PAX6 from its control region, explaining classic aniridia after prior testing was negative.
A double-blind randomized trial found that a single intraoperative intravitreal bevacizumab injection improved 3-year trabeculectomy survival and reduced postoperative medication needs versus placebo.
In a large retrospective glaucoma cohort, delayed follow-up was common yet was not generally associated with visual field worsening, although longer delays appeared more consequential in eyes with worse baseline visual field loss.
This review synthesizes evidence on improving geographic atrophy trial efficiency through innovative run-in phases, single-arm designs, and superior functional biomarkers like microperimetry to reduce required sample sizes.
A new consensus statement advises cautious, shared decision-making about GLP-1 receptor agonists and NAION risk, noting that current evidence is observational, conflicting, and suggests any absolute risk increase is small.
Open language-specific specialty feeds and department pages.